There might be a better way to screen for prostate cancer

An experimental blood test that looks at the activity of six genes linked to prostate tumors could greatly improve the accuracy of PSA testing and "could spare tens of thousands of men from undergoing prostate biopsy each year" if validated in further studies, Dr. Robert W. Ross of Harvard Medical School's Dana-Farber Cancer Institute in Boston told researchers.

Together, the two tests detect cancer accurately more than 90% of the time, compared with only about 60% to 70% for the PSA test alone.